2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Drug Development, Biological Therapies, Antibody Therapy, Checkpoint Inhibitor, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Computer Vision, Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, Fundamental Science, AML, Translational Research, MDS, CMML, Clinical Research, Patient-Reported Outcomes, Study Population, Human, Adult, Elderly, Young Adult
PAPER

2063 Characterization and therapeutic targeting of a disease-driving CD64+ HSPC cluster in chronic myelomonocytic leukemia (CMML)

Traci Kruer, PhD, Maria Balasis2, Amy McLemore, MS3, Zena Komrokji4, Surendra Neupane, PhD5, Angely Pinales6, Sanam Loghavi, MD7, Adriana Del Pino Herrera8, Miguel Martinez9, Nana Adjoa Dankyi, MBChB, PhD10, Louay Hasanin11, Alejandra García, PhD12, Constanza Marin, PhD13, Cintia Garro, PhD14, Maria Lia Buffa15, Omar Abdel-Wahab, MD16, Dan Avi Landau, MD, PhD17, Mrinal M. Patnaik, MD, MBBS18, Eric Solary, MD19, Christopher Ryder, MD PhD20, Meghan Ferrallfairbanks, PhD21, Guillermo Montalban-Bravo, MD22, Gaston Soria, PhD23, Eric Padron, MD24
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Moffitt Cancer Center, Tampa, Florida, United States
4 Moffitt Cancer Center, Tampa, Florida, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 MD Anderson Cancer Center, Houston, Texas, United States
8 University of Florida, Gainesville, Florida, United States
9 University of Florida, Gainesville, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 OncoPrecision, New York, New York, United States
13 OncoPrecision, New York, New York, United States
14 OncoPrecision, New York, New York, United States
15 OncoPrecision, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Weill Cornell Medical College, New York, New York, United States
18 Mayo Clinic, Rochester, Minnesota, United States
19 Gustave Roussy, Villejuif, France
20 Moffitt Cancer Center, Tampa, Florida, United States
21 University of Florida, Gainesville, Florida, United States
22 MD Anderson Cancer Center, Houston, Texas, United States
23 OncoPrecision, New York, New York, United States
24 Moffitt Cancer Center, Tampa, Florida, United States

CMML is a lethal hematopoietic stem and progenitor cell (HSPC) neoplasm characterized by classical monocytosis, cytopenias, and a propensity for acute myeloid leukemia transformation. Unfortunately, no therapies have been devised to target CMML HSPCs. With the goal of credentialing targetable disease-driving HSPC states, we generated a large clinically annotated CMML CITE-seq atlas (n=307 patients) enabling us to catalog canonical HSPC proportions (Abstract abs26-12856) and characterize an aberrant CD34+ HSPC state (Cluster 2) previously observed in a pilot CMML scRNA-seq study. We assigned Cluster 2 cells in our CITE-seq atlas via a single-cell transcriptional signature and observed that higher Cluster 2 abundance was associated with inferior overall survival (OS) and progression-free survival (PFS) in univariate and multivariate analyses. We also confirmed that these cells were nearly absent in our healthy CD34+ control cells and in a large 300,000 normal bone marrow cell reference (Zhang et al., Nat Imm 2024). We next leveraged our CITE-seq data to identify CD34+CD117lo/-CD64+ as the immunophenotype that best approximates RNA-seq defined Cluster 2 cells with an AUC of 0.74. Like RNA-defined Cluster 2 cells, immunophenotypically-defined Cluster 2 cells were associated with inferior OS and PFS in our CITE-seq atlas and in an external clinical flow cytometry cohort that enabled Cluster 2 detection. To determine if Cluster 2 cells are clonogenic we devised a sorting strategy that isolated granulocyte-monocyte progenitors (GMPs) and Cluster 2 cells from 10 CMML patients (pts). While both showed immature morphology, sorted Cluster 2 cells demonstrated larger, monoblastic cytology relative to GMPs. Moreover, while GMPs robustly generated colonies in methylcellulose across a range of cytokines, Cluster 2 cells had no clonogenic capacity across all pts. Given this, we explored the possibility that Cluster 2 cells could instead enhance clonogenicity of other CD34+ cells. To test this, we removed Cluster 2 cells from the CD34+ compartment of 6 CMML pts and added back increasing concentrations of these cells (0-50%) which showed a Cluster 2 cell percentage-dependent increase in clonogenicity across all pts. Collectively this suggests that while Cluster 2 cells do not have clonogenic capacity, they may enhance the clonogenic and leukemia initiating capacity (LIC) of other progenitors. Last, to determine whether Cluster 2 cells can be therapeutically targeted we tested ONC001 in vitro and in vivo in CMML primary cells. ONC001 is a CD64 antibody-drug conjugate designed with a payload that is effective in low cycling HSPCs. CD64 protein was uniquely expressed in Cluster 2 cells among canonical CD34+ HSPC subsets making ONC001 uniquely suited as a preclinical therapy for this aberrant cell state. We performed colony formation assays using samples from 5 unique CMML pts and observed a dose-dependent (nM range) decrease in clonogenicity in ONC001-treated cells. We next generated PDX models from these 5 pts randomizing them to three groups (n=6 mice/group/pt) treated with vehicle, azacitidine, or ONC001. First, half the mice were sacrificed 7 days after a single dose of ONC001 (1 mg/kg) or 5-day treatment with azacitidine (2 mg/kg). The remaining mice were evaluated for OS comparing vehicle mice to mice treated with biweekly ONC001 or azacitidine for 5 consecutive days every 28 days. Engraftment was evaluated in bone marrow (BM), peripheral blood (PB) and spleen (SP). A single dose of ONC001 uniquely led to a profound decrease in human CD45 and CD33 engraftment in the BM, PB, and SP, as well as a significant depletion of classical monocytes across all 5 pt PDX. On-target depletion of CD64+ cells was seen in all compartments but most predominantly in BM. Interestingly, the magnitude of reduction in human engraftment correlated with baseline Cluster 2 percentage of the patient sample. While survival experiments are still ongoing, experiments that have reached endpoint displayed 100% survival of ONC001 treated mice at 120 days (predetermined endpoint), while vehicle and azacitidine treated groups succumbed to leukemia with a median OS of 47 and 83 days, respectively. Results of OS in all PDX and ongoing experiments establishing the role of Cluster 2 on CD34+ CMML LIC in vivo will be reported at time of presentation. Collectively, these data provide strong preclinical rationale for targeting Cluster 2 cells in CMML.

Traci Kruer, PhD: No relevant conflicts of interest to declare.